Mechanisms and strategies for safe chimeric antigen receptor T‐cell activity control
International Journal of Cancer · 15.11.2023 · 153 (10) · 1706-1725
DOI: 10.1002/ijc.34635 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Cancer, online erschienen am 23.06.2023. Verfasst von Sophia Stock und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacology, Department of Medicine IV, LMU University Hospital, Ludwig-Maximilians-Universität München (LMU), Munich, Germany. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Neurotoxicity Syndromes, Neoplasms, Hematologic Neoplasms. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 200 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: European Research Council, Bayerische Forschungsstiftung, Bundesministerium für Bildung und Forschung.
Abstract (Originalsprache)
The clinical application of chimeric antigen receptor (CAR) T‐cell therapy has rapidly changed the treatment options for terminally ill patients with defined blood‐borne cancer types. However, CAR T‐cell therapy can lead to severe therapy‐associated toxicities including CAR‐related hematotoxicity, ON‐target OFF‐tumor toxicity, cytokine release syndrome (CRS) or immune effector cell‐associated neurotoxicity syndrome (ICANS). Just as CAR T‐cell therapy has evolved regarding receptor design, gene transfer systems and production protocols, the management of side effects has also improved. However, because of measures taken to abrogate adverse events, CAR T‐cell viability and persistence might be impaired before complete remission can be achieved. This has fueled efforts for the development of extrinsic and intrinsic strategies for better control of CAR T‐cell activity. These approaches can mediate a reversible resting state or irreversible T‐cell elimination, depending on the route chosen. Control can be passive or active. By combination of CAR T‐cells with T‐cell inhibiting compounds, pharmacologic control, mostly independent of the CAR construct design used, can be achieved. Other strategies involve the genetic modification of T‐cells or further development of the CAR construct by integration of molecular ON/OFF switches such as suicide genes. Alternatively, CAR T‐cell activity can be regulated intracellularly through a self‐regulation function or extracellularly through titration of a CAR adaptor or of a priming small molecule. In this work, we review the current strategies and mechanisms to control activity of CAR T‐cells reversibly or irreversibly for preventing and for managing therapy‐associated toxicities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Clinical Pharmacology, Department of Medicine IV, LMU University Hospital, Ludwig-Maximilians-Universität München (LMU), Munich, Germany.
- Department of Medicine III, LMU University Hospital, Ludwig-Maximilians-Universität München (LMU), Munich, Germany.
- German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany.
- Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany.
- Einheit für Klinische Pharmakologie (EKLiP), Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Neuherberg, Germany.
ORCID-Profile: Sophia Stock
Förderung
- European Research Council
- Bayerische Forschungsstiftung
- Bundesministerium für Bildung und Forschung
- Deutsche Forschungsgemeinschaft
- Deutsche Krebshilfe
- Hector Stiftung
Zitieren
APA
Stock, S., Klüver, A. K., Fertig, L., Menkhoff, V. D., Subklewe, M., Endres, S., & Kobold, S. (2023). Mechanisms and strategies for safe chimeric antigen receptor T‐cell activity control. International Journal of Cancer, 153(10), 1706-1725. https://doi.org/10.1002/ijc.34635
Vancouver
Stock S, Klüver AK, Fertig L, Menkhoff VD, Subklewe M, Endres S, et al. Mechanisms and strategies for safe chimeric antigen receptor T‐cell activity control. International Journal of Cancer. 2023;153(10):1706-1725. doi:10.1002/ijc.34635
BibTeX
@article{Stock2023,
author = {Stock, Sophia and Klüver, Anna-Kristina and Fertig, Luisa and Menkhoff, Vivien D and Subklewe, Marion and Endres, Stefan and Kobold, Sebastian},
title = {Mechanisms and strategies for safe chimeric antigen receptor T‐cell activity control},
journal = {International Journal of Cancer},
year = {2023},
volume = {153},
number = {10},
pages = {1706--1725},
doi = {10.1002/ijc.34635}
}
EUVIMED